CD19 and mesothelioma: These findings were recapitulated in several immunotherapy‐refractory tumor models, including CD19+ Nalm6 xenograft leukemia model, mesothelioma subcutaneous models (M28), and models expressing human CD19 on B16‐F10 melanoma (B16‐hCD19+).1